Australia's clinical stage biopharma firm Akaal Pharma has decided to extend its engagement with GVK Bio of Hyderabad. Announcing this on Wednesday, a statement from GVK Bio said that it will support the scale-up of Akaal's novel topical AKP-11 ointment to support phase-II clinical study in psoriasis.
The formulation development business unit of GVK in Bengaluru has developed robust and scalable process for the ointment.
"GVK Bio plans to support clinical studies of Akaal Pharma’s topical psoriasis drug by providing clinical supplies, manufacturing and analytical support", a release said.
Discussions are underway to work towards exploring appropriate commercialisation packaging and various formulations for the topical use in other inflammatory diseases, GVK Bio said.
Senior Vice President (Formulation R&D) Seetharaju Gembali said: “Strengthening of the partnership is testimonial to our expertise in the formulation development.”
Akaal Pharma CEO Dale Dhanoa said: “We have had a very efficient CRO relationship with GVK for our clinical trial supplies."
